Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation

Bone Marrow Transplantation

Volumn 45, Issue 4, 2010, Pages 798-800

  Rumi, E ^a   Passamonti, F ^a   Arcaini, L ^a   Bernasconi, P ^a   Elena, C ^a   Pietra, D ^a   Brisci, A ^b   Arbustini, E ^a   Cazzola, M ^a   Lazzarino, M ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; GANCICLOVIR; THROMBOPOIETIN RECEPTOR;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; BONE MARROW BIOPSY; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DISEASE MARKER; DNA DENATURATION; GENE MUTATION; GENE SEQUENCE; HETEROZYGOTE; HISTOCOMPATIBILITY; HUMAN; HUMAN TISSUE; LETTER; LEUKOPENIA; MALE; MUTATIONAL ANALYSIS; MYELOABLATIVE CONDITIONING; MYELOFIBROSIS; PRIORITY JOURNAL; REMISSION; SPLENOMEGALY; SURVIVAL; THROMBOCYTHEMIA; VIRUS REACTIVATION;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM, RESIDUAL; PRIMARY MYELOFIBROSIS; RECEPTORS, THROMBOPOIETIN; THROMBOCYTHEMIA, ESSENTIAL; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS;

EID: 77950629185     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.231     Document Type: Letter

References (10)

1. Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21: 270-276. (Pubitemid 46158119)
2. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437-438.
3. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912-3918. (Pubitemid 37486970)
4. Gupta V, Kroger N, Aschan J, Xu W, Leber B, Dalley C et al. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplant 2009 (e-pub ahead of print 23 February 2009).
5. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790. (Pubitemid 40570926)
6. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.
7. Kroger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhauser M et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007; 109: 1316-1321. (Pubitemid 46220685)
8. Benjamini O, Koren-Michowitz M, Amariglio N, Kroger N, Nagler A, Shimoni A. Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Leukemia 2008; 22: 1961-1963.
9. Pietra D, Rumi E, Brisci A, Passamonti F, Boggi S, Cremonesi L et al. Loss of heterozygosity of chromosome 1p34 and high mutant allele burden in patients with post-essential thrombocythemia myelofibrosis carrying somatic mutations of Mpl. Blood 2008; 112: 176a.
10. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497-1503. (Pubitemid 44316114)